样式: 排序: IF: - GO 导出 标记为已读
-
Prospective open-label trial with rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy not responding to conventional immune therapies J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-10 Pietro Emiliano Doneddu, Dario Cocito, Raffaella Fazio, Luana Benedetti, Erdita Peci, Giuseppe Liberatore, Yuri Matteo Falzone, Francesco Germano, Francesca Gallia, Claudia Giannotta, Cinta Lleixà, Elisa Bianchi, Eduardo Nobile-Orazio
Background To evaluate the efficacy of rituximab in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) patients not responding to conventional immune therapies. Methods An open-label, prospective exploratory study was conducted with intravenous rituximab on 17 CIDP patients who had not responded to at least two first-line therapies. The primary endpoint was to determine the proportion
-
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a trial and open-label extension study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-10 Luis Querol, Jérôme De Sèze, Tina Dysgaard, Todd Levine, T Hemanth Rao, Michael Rivner, Hans-Peter Hartung, Peter Kiessling, Saori Shimizu, Dominika Marmol, Ali Bozorg, Anny-Odile Colson, Ute Massow, Filip Eftimov
Background Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a peripheral nerve disorder characterised by weakness and sensory loss. We assessed the neonatal Fc receptor inhibitor rozanolixizumab for CIDP management. Methods CIDP01 ([NCT03861481][1]) was a randomised, subject-blind, investigator-blind, placebo-controlled, phase 2a study. Adults with definite or probable CIDP receiving
-
CIDP trials and tribulations J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-10 Simon Rinaldi
Two publications in JNNP explore the potential utility of therapies with differing mechanisms of action for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Querol et al evaluate the neonatal Fc receptor blocker rozanolixizumab, while Doneddu et al study the anti-CD20 therapeutic monoclonal rituximab.1 2 These agents, respectively, lower serum IgG levels or primarily
-
Phase 1 study of safety and preliminary efficacy of intranasal transplantation of human neural stem cells (ANGE-S003) in Parkinson’s disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-09 Shenzhong Jiang, Han Wang, Chengxian Yang, Feng Feng, Dan Xu, Mengyu Zhang, Manqing Xie, Ruixue Cui, Zhaohui Zhu, Chenhao Jia, Linwen Liu, Lin Wang, Xunzhe Yang, Yingmai Yang, Honglin Hao, Zhaoxi Liu, Zhihong Wu, Ling Leng, Xiaoxin Li, Xicai Sun, Xiongfei Zhao, Jinfang Xu, Yi Zhang, Xinhua Wan, Xinjie Bao, Renzhi Wang
Background Intranasal transplantation of ANGE-S003 human neural stem cells showed therapeutic effects and were safe in preclinical models of Parkinson’s disease (PD). We investigated the safety and tolerability of this treatment in patients with PD and whether these effects would be apparent in a clinical trial. Methods This was a 12-month, single-centre, open-label, dose-escalation phase 1 study of
-
Neurophysiological features of STN LFP underlying sleep fragmentation in Parkinson’s disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-09 Guokun Zhang, Huiling Yu, Yue Chen, Chen Gong, Hongwei Hao, Yi Guo, Shujun Xu, Yuhuan Zhang, Xuemei Yuan, Guoping Yin, Jian-guo Zhang, Huiling Tan, Luming Li
Background Sleep fragmentation is a persistent problem throughout the course of Parkinson’s disease (PD). However, the related neurophysiological patterns and the underlying mechanisms remained unclear. Method We recorded subthalamic nucleus (STN) local field potentials (LFPs) using deep brain stimulation (DBS) with real-time wireless recording capacity from 13 patients with PD undergoing a one-night
-
Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-06 Adil Maarouf, Jan Patrick Stellmann, Audrey Rico, Clemence Boutiere, Sarah Demortiere, Pierre Durozard, Wafaa Zaaraoui, Jean-Philippe Ranjeva, Jean Pelletier, Bertrand Audoin
Background Progression independent of relapse activity (PIRA) has been described since the early stage of relapsing multiple sclerosis (RMS). However, little is known about the relation between PIRA and inflammatory activity that is particularly important at this stage of the disease. Method We included 110 patients in a prospective study within 18 months of RMS onset. MRI examinations and clinical
-
A phase I trial of accelerated intermittent theta burst rTMS for amnestic MCI J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-06 Stephanie Aghamoosa, James Lopez, Katrina Rbeiz, Holly H Fleischmann, Olivia Horn, Katrina Madden, Kevin A Caulfield, Michael U Antonucci, Gonzalo Revuelta, Lisa M McTeague, Andreana Benitez
Background Emerging evidence suggests that repetitive transcranial magnetic stimulation (rTMS) enhances cognition in mild cognitive impairment (MCI). Accelerated intermittent theta burst stimulation (iTBS) rTMS protocols are promising as they substantially reduce burden by shortening the treatment course, but the safety, feasibility, and acceptability of iTBS have not been established in MCI. Methods
-
Weighing the impact of post hoc studies J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-26 Karen L Furie
In their JNNP study, Dr Sun et al report post hoc analyses of data from the ‘Minimally Invasive Surgery plus Alteplase for Intracerebral haemorrhage Evacuation trial (MISTIE III)’.1 2 The parent study was a randomised open-label trial comparing image-guided minimally invasive haematoma evacuation followed by alteplase irrigation (MIS+alteplase) to standard medical care. The primary endpoint of the
-
Does stereotactic thrombolysis with alteplase for intracerebral haemorrhage alter intraventricular haematoma volume? A secondary analysis of the MISTIE-III trial J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-26 Philip Sun, Shervin Badihian, Radhika Avadhani, Nathan Walborn, Anusha Yarava, Donya Alimoradi, Issam Awad, Daniel Hanley, Santosh Murthy, Wendy Ziai
Background Stereotactic thrombolysis reduces intracerebral haemorrhage (ICH) volume in patients with spontaneous ICH. Whether intrahaematomal alteplase administration is associated with a change in intraventricular haemorrhage volume (deltaIVH) and functional outcomes is unknown. Methods Post hoc secondary analysis of the Minimally Invasive Surgery plus Alteplase for Intracerebral Hemorrhage Evacuation
-
Identification of DAGLA as an autoantibody target in cerebellar ataxia J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-25 Ramona Miske, Madeleine Scharf, Kathrin Borowski, Ina Specht, Merle Corty, Monika-Johanna Loritz, Frederik Rombach, Guy Laureys, Nadine Rochow, Christiane Radzimski, Linda Schnitter, Dominica Ratuszny, Thomas Skripuletz, Mike P Wattjes, Stefanie Hahn, Yvonne Denno, Khadija Guerti, Matthijs Oyaert, Farid Benkhadra, Corinna Ines Bien, Sophie Nitsch, Klaus-Peter Wandinger, Vincent van Pesch, Christian
Background We aimed to investigate the clinical, imaging and fluid biomarker characteristics in patients with antidiacylglycerol lipase alpha (DAGLA)-autoantibody-associated cerebellitis. Methods Serum and cerebrospinal fliud (CSF) samples from four index patients were subjected to comprehensive autoantibody screening by indirect immunofluorescence assay (IIFA). Immunoprecipitation, mass spectrometry
-
Genetics impact risk of Alzheimer’s disease through mechanisms modulating structural brain morphology in late life J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-25 Roxanna Korologou-Linden, Bing Xu, Elizabeth Coulthard, Esther Walton, Alfie Wearn, Gibran Hemani, Tonya White, Charlotte Cecil, Tamsin Sharp, Henning Tiemeier, Tobias Banaschewski, Arun Bokde, Sylvane Desrivières, Herta Flor, Antoine Grigis, Hugh Garavan, Penny Gowland, Andreas Heinz, Rüdiger Brühl, Jean-Luc Martinot, Marie-Laure Paillère Martinot, Eric Artiges, Frauke Nees, Dimitri Papadopoulos Orfanos
Background Alzheimer’s disease (AD)-related neuropathological changes can occur decades before clinical symptoms. We aimed to investigate whether neurodevelopment and/or neurodegeneration affects the risk of AD, through reducing structural brain reserve and/or increasing brain atrophy, respectively. Methods We used bidirectional two-sample Mendelian randomisation to estimate the effects between genetic
-
Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-24 Sylvain Lehmann, Susanna Schraen-Maschke, Jean-Sébastien Vidal, Constance Delaby, Luc Buee, Frédéric Blanc, Claire Paquet, Bernadette Allinquant, Stéphanie Bombois, Audrey Gabelle, Olivier Hanon
Background Among plasma biomarkers for Alzheimer’s disease (AD), pTau181 and pTau217 are the most promising. However, transition from research to routine clinical use will require confirmation of clinical performance in prospective cohorts and evaluation of cofounding factors. Method pTau181 and pTau217 were quantified using, Quanterix and ALZpath, SIMOA assays in the well-characterised prospective
-
Contribution of basal ganglia activity to REM sleep disorder in Parkinson’s disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-19 Zixiao Yin, Tianshuo Yuan, Anchao Yang, Yichen Xu, Guanyu Zhu, Qi An, Ruoyu Ma, Yifei Gan, Lin Shi, Yutong Bai, Ning Zhang, Chunxue Wang, Yin Jiang, Fangang Meng, Wolf-Julian Neumann, Huiling Tan, Jian-Guo Zhang
Background Rapid eye movement (REM) sleep behaviour disorder (RBD) is one of the most common sleep problems and represents a key prodromal marker in Parkinson’s disease (PD). It remains unclear whether and how basal ganglia nuclei, structures that are directly involved in the pathology of PD, are implicated in the occurrence of RBD. Method Here, in parallel with whole-night video polysomnography, we
-
Pain related to MRgFUS: a merely minor transient adverse event? J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-19 Paolo Amami, Sara Prioni, Marco Fusar Poli, Riccardo Pascuzzo, Elisa Bocchi, Nico Golfrè Andreasi, Grazia Devigili, Roberto Cilia, Sara Rinaldo, Vincenzo Levi, Francesco Ghielmetti, Marina Grisoli, Marco Gemma, Francesco DiMeco, Roberto Eleopra, Sylvie Piacentini
MR-guided focused ultrasound (MRgFUS) of the ventral intermediate (VIM) nucleus of the thalamus has recently emerged as a novel treatment option for medically refractory tremor in essential tremor and tremor-dominant Parkinson’s disease. The patient’s collaboration is crucial during MRgFUS, as intraoperative testing phases are performed during which tremor severity and any eventual side effects are
-
Increased apathy post-interstitial laser capsulotomy for refractory obsessive–compulsive disorder J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-16 Hannah A Hagy, Maureen Lacy, Nataliya Turchmanovych-Hienkel, Jon E Grant, Daniel Biro, Peter C Warnke
Background MRI guided laser interstitial thermal therapy (M-LITT) capsulotomy has proven to be efficacious in decreasing refractory obsessive-compulsive disorder (OCD) related symptomatology yet capsulotomy either via radiosurgery or radiofrequency ablation has in some patients led to increased apathy following surgery. The current case series aims to investigate objective patient-reported change in
-
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS) J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Marcus Koch
In JNNP , Toorop and coworkers present the results of the NEXT-MS trial, a clinical trial on individualised extended interval dosing (EID) of natalizumab (NTZ) in people with relapsing-remitting multiple sclerosis (RRMS).1 NTZ was one of the first high-efficacy treatments in RRMS, and has remained popular since its introduction in the late 2000s. NTZ is typically administered at a dose of 300 mg every
-
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS) J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Alyssa A Toorop, Zoë YGJ van Lierop, Liza MY Gelissen, Elske Hoitsma, Esther MPE Zeinstra, Luuk C van Rooij, Caspar EP van Munster, Anke Vennegoor, Jop P Mostert, Beatrijs HA Wokke, Nynke F Kalkers, Erwin LJ Hoogervorst, Jeroen JJ van Eijk, Christiaan M Roosendaal, Jolijn J Kragt, Marijke Eurelings, Jessie van Genugten, Jessica Nielsen, LGF Sinnige, Mark E Kloosterziel, Edo PJ Arnoldus, Gert W van
Background Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension of treatment intervals. Methods The NEXT-MS trial is an investigator-initiated prospective phase IV non-randomised study. Adults with a diagnosis of relapsing-remitting MS who received ≥6 natalizumab
-
Exploring the cost-effectiveness of EBV vaccination to prevent multiple sclerosis in an Australian setting J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Andrew J Palmer, Ting Zhao, Bruce V Taylor, Ingrid van der Mei, Julie A Campbell
Background Increasing evidence suggests the potential of Epstein-Barr virus (EBV) vaccination in preventing multiple sclerosis (MS). We aimed to explore the cost-effectiveness of a hypothetical EBV vaccination to prevent MS in an Australian setting. Methods A five-state Markov model was developed to simulate the incidence and subsequent progression of MS in a general Australian population. The model
-
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Nicolás Fissolo, Pascal Benkert, Jaume Sastre-Garriga, Neus Mongay-Ochoa, Andreu Vilaseca-Jolonch, Sara Llufriu, Yolanda Blanco, Harald Hegen, Klaus Berek, Francisco Perez-Miralles, Konrad Rejdak, Luisa M Villar, Enric Monreal, Roberto Alvarez-Lafuente, Onder K Soylu, Ahmed Abdelhak, Franziska Bachhuber, Hayrettin Tumani, Sergio Martínez-Yélamos, Antonio J Sánchez-López, Antonio García-Merino, Lucía
Background We aimed to investigate the potential of serum biomarker levels to predict disability progression in a multicentric real-world cohort of patients with primary progressive multiple sclerosis (PPMS). Methods A total of 141 patients with PPMS from 18 European MS centres were included. Disability progression was investigated using change in Expanded Disability Status Scale (EDSS) score over
-
Predictive value of retinal atrophy for cognitive decline across disease duration in multiple sclerosis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Salut Alba-Arbalat, Elisabeth Solana, Elisabet Lopez-Soley, Anna Camos-Carreras, Eloy Martinez-Heras, Francesc Vivó, Irene Pulido-Valdeolivas, Magi Andorra, Maria Sepulveda, Jose María Cabrera, Elianet Fonseca, Alberto Calvi, Rafel Alcubierre, Marina Dotti-Boada, Albert Saiz, Elena H Martinez-Lapiscina, Pablo Villoslada, Yolanda Blanco, Bernardo Sanchez-Dalmau, Sara Llufriu
Background We investigated the association between changes in retinal thickness and cognition in people with MS (PwMS), exploring the predictive value of optical coherence tomography (OCT) markers of neuroaxonal damage for global cognitive decline at different periods of disease. Method We quantified the peripapillary retinal nerve fibre (pRFNL) and ganglion cell-inner plexiform (GCIPL) layers thicknesses
-
Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease course J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Omar Abdel-mannan, Dimitrios Champsas, Carmen Tur, Vanessa Lee, Sharmila Manivannan, Haroon Usman, Alison Skippen, Ishita Desai, Manali Chitre, Rob Forsyth, Rachel Kneen, Dipak Ram, Sithara Ramdas, Thomas Rossor, Siobhan West, Sukhvir Wright, Jacqueline Palace, Evangeline Wassmer, Cheryl Hemingway, Ming J Lim, Kshitij Mankad, Olga Ciccarelli, Yael Hacohen
Background Lesion resolution is often observed in children with myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD), and asymptomatic lesions are less commonly reported in MOGAD than in multiple sclerosis (MS). Objective We aimed to evaluate brain MRI changes over time in paediatric MOGAD. Methods Retrospective study in eight UK paediatric neuroscience centres. Acute brain MRI and
-
Use, tolerability, benefits and side effects of orthotic devices in Charcot-Marie-Tooth disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Alessandro Bertini, Fiore Manganelli, Gian Maria Fabrizi, Angelo Schenone, Lucio Santoro, Tiziana Cavallaro, Matteo Tagliapietra, Marina Grandis, Stefano Carlo Previtali, Yuri Matteo Falzone, Isabella Allegri, Luca Padua, Costanza Pazzaglia, Irene Tramacere, Eleonora Cavalca, Paola Saveri, Andrea Quattrone, Paola Valentino, Stefano Tozza, Luca Gentile, Massimo Russo, Anna Mazzeo, Giuseppe Vita, Valeria
Background Shoe inserts, orthopaedic shoes, ankle-foot orthoses (AFOs) are important devices in Charcot-Marie-Tooth disease (CMT) management, but data about use, benefits and tolerance are scanty. Methods We administered to Italian CMT Registry patients an online ad hoc questionnaire investigating use, complications and perceived benefit/tolerability/emotional distress of shoe inserts, orthopaedic
-
Effectiveness of conservative non-pharmacological interventions in people with muscular dystrophies: a systematic review and meta-analysis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Enza Leone, Anand Pandyan, Alison Rogers, Richa Kulshrestha, Jonathan Hill, Fraser Philp
Introduction Management of muscular dystrophies (MD) relies on conservative non-pharmacological treatments, but evidence of their effectiveness is limited and inconclusive. Objective To investigate the effectiveness of conservative non-pharmacological interventions for MD physical management. Methods This systematic review and meta-analysis followed Preferred Reporting Items for Systematic Reviews
-
Methodological considerations for observational studies of treatment effectiveness in neurology: a clinician’s guide J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Tomas Kalincik, Izanne Roos, Sifat Sharmin, Charles B Malpas
Data from cohorts, registries, randomised trials, electronic medical records and administrative claims databases have increasingly been used to inform the use of therapies for neurological diseases. While novel sophisticated methods are enabling us to use existing data to guide treatment decisions, the complexity of statistical methodology is making appraisal of clinical evidence increasingly demanding
-
Unravelling the influence of affective stimulation on functional neurological symptoms: a pilot experiment examining potential mechanisms J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Susannah Pick, LS Merritt Millman, Emily Ward, Eleanor Short, Biba Stanton, AAT Simone Reinders, Joel S Winston, Timothy R Nicholson, Mark J Edwards, Laura H Goldstein, Anthony S David, Trudie Chalder, Matthew Hotopf, Mitul A Mehta
Background Differences in affective processing have previously been shown in functional neurological disorder (FND); however, the mechanistic relevance is uncertain. We tested the hypotheses that highly arousing affective stimulation would result in elevated subjective functional neurological symptoms (FNS), and this would be associated with elevated autonomic reactivity. The possible influence of
-
Pragmatic computerised perfusion diagnostics for non-convulsive status epilepticus: a prospective observational study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Elena Merli, Michele Romoli, Simone Galluzzo, Lorenzo Bevacqua, Emanuele Saverio Cece, Gabriele Ricci, Stefania Testoni, Anna Zaniboni, Maria Maddalena Viola, Luigi Simonetti, Francesca Bisulli, Sara Contardi, Paolo Tinuper, Andrea Zini
Background Non-convulsive status epilepticus (NCSE) is a time-dependent neurological disorder often misdiagnosed in the emergency setting. Electroencephalography (EEG) is often not available on a 24/7 basis, and Salzburg criteria may at times miss the diagnosis. Here, we tested the accuracy of hyperperfusion on CT perfusion imaging (CTP) in the identification of NCSE against Salzburg criteria, to define
-
Binary reversals: a diagnostic sign in primary progressive aphasia J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Eoin Mulroy, Lucy B Core, Anthipa Chokesuwattanaskul, Jeremy CS Johnson, Phillip D Fletcher, Charles R Marshall, Anna Volkmer, Jonathan D Rohrer, Chris JD Hardy, Martin N Rossor, Jason D Warren
Background Binary reversals (exemplified by ‘yes’/‘no’ confusions) have been described in patients with primary progressive aphasia (PPA) but their diagnostic value and phenotypic correlates have not been defined. Methods We conducted a retrospective cohort study analysing demographic, clinical, neuropsychological, linguistic and behavioural data from patients representing all major PPA syndromes
-
Clinical biomarker-based biological ageing and future risk of neurological disorders in the UK Biobank J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Jonathan K L Mak, Christopher E McMurran, Sara Hägg
Background Many common neurological disorders are associated with advancing chronological age, but their association with biological age (BA) remains poorly understood. Methods We studied 325 870 participants in the UK Biobank without a diagnosed neurological condition at baseline and generated three previously-described measures of BA based on 18 routinely measured clinical biomarkers (PhenoAge, Klemera-Doubal
-
Haemorrhagic myelitis as a manifestation of MOG antibody-associated disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-05-01 Jonathan Ciron, Damien Biotti, Chloé Bost, Fabrice Bonneville, Romain Marignier
We read with interest the recent article ‘MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes’ by Lee et al 1 and the letter to the editor entitled ‘Acute haemorrhagic leucoencephalitis as clinical manifestation of MOG antibody-associated disease’ by Skarsta et al .2 In the first article, the authors illustrate three different phenotypes of MOG (myelin oligodendrocyte glycoprotein)
-
Effects of high-intensity interval training and moderate-intensity continuous training on non-motor symptoms in patients with Parkinson’s disease: a randomised pilot trial J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-05 Ryul Kim, Seohee Choi, Nyeonju Kang, Kiwon Park, Heehyun Shin, Hanall Lee, Hyungwoo Lee, Jin-Sun Jun, Beomseok Jeon, Kyeongho Byun
The benefits of engaging in regular exercise for individuals with Parkinson’s disease (PD) have been widely recognised.1 With respect to non-motor symptoms, previous studies have demonstrated the efficacy of physical exercises on cognitive function and depressive and sleep-related symptoms.2–4 However, it is largely unknown whether exercise improves other non-motor symptoms and how such effects differ
-
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-03 Cathérine Dekeyser, Matthias Hautekeete, Melissa Cambron, Vincent Van Pesch, Francesco Patti, Jens Kuhle, Samia Khoury, Jeanette Lechner Scott, Oliver Gerlach, Alessandra Lugaresi, Davide Maimone, Andrea Surcinelli, Pierre Grammond, Tomas Kalincik, Mario Habek, Barbara Willekens, Richard Macdonell, Patrice Lalive, Tunde Csepany, Helmut Butzkueven, Cavit Boz, Valentina Tomassini, Matteo Foschi, José
Background It remains unclear whether routine cerebrospinal fluid (CSF) parameters can serve as predictors of multiple sclerosis (MS) disease course. Methods This large-scale cohort study included persons with MS with CSF data documented in the MSBase registry. CSF parameters to predict time to reach confirmed Expanded Disability Status Scale (EDSS) scores 4, 6 and 7 and annualised relapse rate in
-
Trends in the prevalence and pharmacological management of migraine during pregnancy in the UK, 2000–2018 J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-03 Katherine Phillips, Krishnarajah Nirantharakumar, Benjamin R Wakerley, Francesca L Crowe
Background Migraine is common in women of reproductive age. This study aimed to (1) describe the prevalence of migraine in pregnant women in the UK, (2) identify drugs commonly prescribed for migraine during pregnancy and (3) identify characteristics associated with being prescribed medication for migraine during pregnancy. Methods The Clinical Practice Research Datalink pregnancy register, a database
-
Peripheral hearing loss at age 70 predicts brain atrophy and associated cognitive change J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-03 Thomas D Parker, Chris Hardy, Sarah Keuss, William Coath, David M Cash, Kirsty Lu, Jennifer M Nicholas, Sarah-Naomi James, Carole Sudre, Sebastian Crutch, Doris-Eva Bamiou, Jason D Warren, Nick C Fox, Marcus Richards, Jonathan M Schott
Background Hearing loss has been proposed as a modifiable risk factor for dementia. However, the relationship between hearing, neurodegeneration, and cognitive change, and the extent to which pathological processes such as Alzheimer’s disease and cerebrovascular disease influence these relationships, is unclear. Methods Data from 287 adults born in the same week of 1946 who underwent baseline pure
-
Prognostic factors for disease activity in newly diagnosed teriflunomide-treated patients with multiple sclerosis: a nationwide Danish study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-03 Mie Reith Mahler, Melinda Magyari, Luigi Pontieri, Frederik Elberling, Rolf Pringler Holm, Arkadiusz Weglewski, Mai Bang Poulsen, Lars Kristian Storr, Plamen Anzhelov Bekyarov, Zsolt Illes, Matthias Kant, Tobias Sejbaek, Morten Leif Stilund, Peter V Rasmussen, Maria Brask, Inga Urbonaviciute, Finn Sellebjerg
Background Clinicians frequently rely on relapse counts, T2 MRI lesion load (T2L) and Expanded Disability Status Scale (EDSS) scores to guide treatment decisions for individuals diagnosed with multiple sclerosis (MS). This study evaluates how these factors, along with age and sex, influence prognosis during treatment with teriflunomide (TFL). Methods We conducted a nationwide cohort study using data
-
Neuroanatomical and prognostic associations of depression in Parkinson’s disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-03 James B Badenoch, Alvar Paris, Benjamin Meir Jacobs, Alastair J Noyce, Charles R Marshall, Sheena Waters
Background Depression is reported as a risk factor, prodromal feature and late consequence of Parkinson’s disease (PD). We aimed to evaluate the timing, neuroanatomy and prognostic implications of depression in PD. Methods We used data from 434 023 participants from UK Biobank with 14.1 years of follow-up. Multivariable regression models established associations of depression with incident PD and regional
-
Validation of the international MOGAD panel proposed criteria: a single-centre US study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-03 Angeliki G Filippatou, Yana Said, Haiwen Chen, Eleni S Vasileiou, Gelareh Ahmadi, Elias S Sotirchos
Background Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) is a demyelinating disorder of the central nervous system. We aimed to evaluate the diagnostic performance of recently proposed MOGAD diagnostic criteria in a real-world patient cohort at a tertiary referral centre. Methods We identified all patients who were evaluated at Johns Hopkins and were MOG-IgG seropositive
-
T cell activation markers CD38 and HLA-DR indicative of non-seroconversion in anti-CD20-treated patients with multiple sclerosis following SARS-CoV-2 mRNA vaccination J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-28 Niels J M Verstegen, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Jet van den Dijssel, Thomas Ashhurst, Laura Y L Kummer, Virginia Palomares Cabeza, Maurice Steenhuis, Mariël C Duurland, Rivka de Jongh, C Ellen van der Schoot, Veronique A L Konijn, Erik Mul, Katherine Kedzierska, Koos P J van Dam, Eileen W Stalman, Laura Boekel, Gertjan Wolbink, Sander W Tas, Joep Killestein, Theo Rispens, Luuk
Background Messenger RNA (mRNA) vaccines provide robust protection against SARS-CoV-2 in healthy individuals. However, immunity after vaccination of patients with multiple sclerosis (MS) treated with ocrelizumab (OCR), a B cell-depleting anti-CD20 monoclonal antibody, is not yet fully understood. Methods In this study, deep immune profiling techniques were employed to investigate the immune response
-
Venous thromboembolism risk in amyotrophic lateral sclerosis: a hospital record-linkage study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-28 Raph Goldacre, Michael Trubshaw, Eva J A Morris, Kevin Talbot, Michael J Goldacre, Alexander Guy Thompson, Martin R Turner
Background Venous thromboembolism (VTE) can occur in amyotrophic lateral sclerosis (ALS) and pulmonary embolism causes death in a minority of cases. The benefits of preventing VTE must be weighed against the risks. An accurate estimate of the incidence of VTE in ALS is crucial to assessing this balance. Methods This retrospective record-linkage cohort study derived data from the Hospital Episode Statistics
-
Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-27 Tomas Kalincik, Sifat Sharmin, Izanne Roos, Jennifer Massey, Ian Sutton, Barbara Withers, Mark S Freedman, Harold Atkins, Eva Krasulova, Eva Kubala Havrdova, Marek Trneny, Tomas Kozak, Joachim Burman, Richard Macdonell, Øivind Torkildsen, Lars Bø, Anne Kristine Lehmann, Basil Sharrack, John Snowden
Background Natalizumab was not shown to modify disability in progressive multiple sclerosis (MS). This matched observational study compared the effectiveness of autologous haematopoietic stem cell transplantation (AHSCT) with natalizumab in progressive MS. Methods Patients with primary/secondary progressive MS from seven AHSCT MS centres and the MSBase registry, treated with AHSCT or natalizumab, were
-
Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-27 John Vissing, Sari Atula, Mari Savolainen, Juha Mehtälä, Laila Mehkri, Tina Bech Olesen, Tero Ylisaukko-oja, Ingrid Lindberg-Schager, Fredrik Berggren, Fredrik Piehl
Background Incidence and prevalence rates of myasthenia gravis (MG) vary considerably across studies, and mortality risk is rarely addressed. We examined the prevalence and incidence rates, mortality and factors associated with mortality with MG. Method This was a registry linkage study based on nationwide health and administrative registries of Denmark, Finland and Sweden (populations of 5.9, 5.6
-
Prevalence of autoimmune diseases in functional neurological disorder: influence of psychiatric comorbidities and biological sex J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-21 Anna Joseph, Gaston Baslet, Mary A O’Neal, Ginger Polich, Irene Gonsalvez, Andrea N Christoforou, Barbara A Dworetzky, Primavera A Spagnolo
Background Functional neurological disorder (FND) is a common and disabling neuropsychiatric condition, which disproportionally affects women compared with men. While the etiopathogenesis of this disorder remains elusive, immune dysregulation is emerging as one potential mechanism. To begin to understand the role of immune dysfunctions in FND, we assessed the prevalence of several common autoimmune
-
Clinicoradiological and neuropathological evaluation of primary progressive aphasia J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-21 Dror Shir, Nick Corriveau-Lecavalier, Camilo Bermudez Noguera, Leland Barnard, Nha Trang Thu Pham, Hugo Botha, Joseph R Duffy, Heather M Clark, Rene L Utianski, David S Knopman, Ronald C Petersen, Bradley F Boeve, Melissa E Murray, Aivi T Nguyen, R Ross Reichard, Dennis W Dickson, Gregory S Day, Walter K Kremers, Neill R Graff-Radford, David T Jones, Mary M Machulda, Julie A Fields, Jennifer L Whitwell
Background Primary progressive aphasia (PPA) defines a group of neurodegenerative disorders characterised by language decline. Three PPA variants correlate with distinct underlying pathologies: semantic variant PPA (svPPA) with transactive response DNA-binding protein of 43 kD (TDP-43) proteinopathy, agrammatic variant PPA (agPPA) with tau deposition and logopenic variant PPA (lvPPA) with Alzheimer’s
-
Circuit-based neuromodulation enhances delayed recall in amnestic mild cognitive impairment J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-19 Jie Ma, Jia-Jia Wu, Xiang-Xin Xing, Xin Xue, Yun-Ting Xiang, Xiao-Min Zhen, Jian-Hua Li, Juan-Juan Lu, Jun-Peng Zhang, Mou-Xiong Zheng, Xu-Yun Hua, Jian-Guang Xu
Background This study aimed to investigate the efficacy of circuits-based paired associative stimulation (PAS) in adults with amnestic mild cognitive impairment (aMCI). Methods We conducted a parallel-group, randomised, controlled clinical trial. Initially, a cohort of healthy subjects was recruited to establish the cortical-hippocampal circuits by tracking white matter fibre connections using diffusion
-
Dissociative seizures in the emergency department: how to solve the problem of diagnostic confusion leading to iatrogenic harm? J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Mahinda Yogarajah
Over the last 20 years, there has been a renaissance in the study of functional neurological disorders (FNDs). Alongside an improved understanding of their involuntary nature,1 and mechanistic and aetiological complexities,2 there is an increasing recognition of the iatrogenic harm and socioeconomic costs associated with these disorders. Dissociative seizures are the most common form of FND. They look
-
Dissociative seizures in the emergency room: room for improvement J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Ozan Cengiz, Johannes Jungilligens, Rosa Michaelis, Jörg Wellmer, Stoyan Popkirov
Background Dissociative seizures, also known as functional or psychogenic non-epileptic seizures, account for 11%–27% of all emergency seizure presentations. Misdiagnosis as epileptic seizures is common and leads to ineffective and potentially harmful treatment escalations. We assess the potential for diagnostic improvement at different stages of emergency workup and estimate the utility of benzodiazepines
-
GPi-DBS-induced brain metabolic activation in cervical dystonia J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Emma A Honkanen, Jaana Rönkä, Eero Pekkonen, Juho Aaltonen, Maija Koivu, Olli Eskola, Hazem Eldebakey, Jens Volkmann, Valtteri Kaasinen, Martin M Reich, Juho Joutsa
Background Deep brain stimulation (DBS) of the globus pallidus interna (GPi) is a highly efficacious treatment for cervical dystonia, but its mechanism of action is not fully understood. Here, we investigate the brain metabolic effects of GPi-DBS in cervical dystonia. Methods Eleven patients with GPi-DBS underwent brain 18F-fluorodeoxyglucose positron emission tomography imaging during stimulation
-
Are patients with GBA–Parkinson disease good candidates for deep brain stimulation? A longitudinal multicentric study on a large Italian cohort J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Micol Avenali, Roberta Zangaglia, Giada Cuconato, Ilaria Palmieri, Alberto Albanese, Carlo Alberto Artusi, Marco Bozzali, Giovanna Calandra-Buonaura, Francesco Cavallieri, Roberto Cilia, Antoniangela Cocco, Filippo Cogiamanian, Fabiana Colucci, Pietro Cortelli, Alessio Di Fonzo, Roberto Eleopra, Giulia Giannini, Alberto Imarisio, Gabriele Imbalzano, Claudia Ledda, Leonardo Lopiano, Maria Chiara Malaguti
Background GBA variants increase the risk of developing Parkinson disease (PD) and influence its outcome. Deep brain stimulation (DBS) is a recognised therapeutic option for advanced PD. Data on DBS long-term outcome in GBA carriers are scarce. Objective To elucidate the impact of GBA variants on long-term DBS outcome in a large Italian cohort. Methods We retrospectively recruited a multicentric Italian
-
Temporal course of cognitive and behavioural changes in motor neuron diseases J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Caroline A McHutchison, Joanne Wuu, Corey T McMillan, Rosa Rademakers, Jeffrey Statland, Gang Wu, Evadnie Rampersaud, Jason Myers, Jessica P Hernandez, Sharon Abrahams, Michael Benatar
Background Cognitive and behavioural dysfunction may occur in people with motor neuron disease (MND), with some studies suggesting an association with the C9ORF72 repeat expansion. Their onset and progression, however, is poorly understood. We explored how cognition and behaviour change over time, and whether demographic, clinical and genetic factors impact these changes. Methods Participants with
-
Seroreactivity against lytic, latent and possible cross-reactive EBV antigens appears on average 10 years before MS induced preclinical neuroaxonal damage J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Daniel Jons, Viktor Grut, Tomas Bergström, Henrik Zetterberg, Martin Biström, Martin Gunnarsson, Magnus Vrethem, Nicole Brenner, Julia Butt, Kaj Blennow, Staffan Nilsson, Ingrid Kockum, Tomas Olsson, Tim Waterboer, Peter Sundström, Oluf Andersen
Background Multiple sclerosis (MS) and presymptomatic axonal injury appear to develop only after an Epstein-Barr virus (EBV) infection. This association remains to be confirmed across a broad preclinical time range, for lytic and latent EBV seroreactivity, and for potential cross-reacting antigens. Methods We performed a case–control study with 669 individual serum samples obtained before clinical
-
Best practices in phase III clinical trials on DMTs for multiple sclerosis: a systematic analysis and appraisal of published trials J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Marta Mascarenas-Garcia, Alejandro Rivero-de-Aguilar, Mónica Pérez-Ríos, Alberto Ruano-Raviña, Miguel Angel Llaneza-Gonzalez, Cristina Candal-Pedreira, Julia Rey-Brandariz, Leonor Varela-Lema
Background Great advances have been made in the field of multiple sclerosis (MS) therapy due to the publication of numerous randomised clinical trials (RCTs). In this study, we carried out a critical appraisal of phase III RCTs of disease-modifying therapies (DMTs) for MS published after 2010, intending to identify critical areas of improvement. Methods We performed a systematic search of published
-
COVID-19 has no impact on disease activity, progression and cognitive performance in people with multiple sclerosis: a 2-year study J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Federico Montini, Agostino Nozzolillo, Nicolò Tedone, Damiano Mistri, Paola MV Rancoita, Chiara Zanetta, Alessandra Mandelli, Roberto Furlan, Lucia Moiola, Vittorio Martinelli, Maria A Rocca, Massimo Filippi
Background Sequelae of COVID-19 in people with multiple sclerosis (PwMS) have not been characterised. We explored whether COVID-19 is associated with an increased risk of disease activity, disability worsening, neuropsychological distress and cognitive dysfunction during the 18–24 months following SARS-COV-2 infection. Methods We enrolled 174 PwMS with history of COVID-19 (MS-COVID) between March 2020
-
Do lower limb motor-evoked potentials predict walking outcomes post-stroke? J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Marie-Claire Smith, Benjamin J Scrivener, Cathy M Stinear
Background This observational study examined whether lower limb (LL) motor-evoked potentials (MEPs) 1 week post-stroke predict recovery of independent walking, use of ankle-foot orthosis (AFO) or walking aid, at 3 and 6 months post-stroke. Methods Non-ambulatory participants were recruited 5 days post-stroke. Transcranial magnetic stimulation was used to determine tibialis anterior MEP status and clinical
-
Alzheimer’s disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Neil Graham, Karl Zimmerman, Amanda J Heslegrave, Ashvini Keshavan, Federico Moro, Samia Abed-Maillard, Adriano Bernini, Vincent Dunet, Elena Garbero, Giovanni Nattino, Arturo Chieregato, Enrico Fainardi, Camelia Baciu, Primoz Gradisek, Sandra Magnoni, Mauro Oddo, Guido Bertolini, Jonathan M Schott, Henrik Zetterberg, David Sharp
Background Traumatic brain injury (TBI) is associated with the tauopathies Alzheimer’s disease and chronic traumatic encephalopathy. Advanced immunoassays show significant elevations in plasma total tau (t-tau) early post-TBI, but concentrations subsequently normalise rapidly. Tau phosphorylated at serine-181 (p-tau181) is a well-validated Alzheimer’s disease marker that could potentially seed progressive
-
Premorbid brain structure influences risk of amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Alexander G Thompson, Bernd Taschler, Stephen M Smith, Martin R Turner
Background Amyotrophic lateral sclerosis (ALS) is a disease of the motor network associated with brain structure and functional connectivity alterations that are implicated in disease progression. Whether such changes have a causal role in ALS, fitting with a postulated influence of premorbid cerebral architecture on the phenotypes associated with neurodegenerative disorders is not known. Methods This
-
The T1-weighted/T2-weighted ratio as a biomarker of anti-NMDA receptor encephalitis J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Tim Julian Hartung, Graham Cooper, Valentin Jünger, Darko Komnenić, Lara Ryan, Josephine Heine, Claudia Chien, Friedemann Paul, Harald Prüss, Carsten Finke
Background Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis rarely causes visible lesions in conventional MRI, yet advanced imaging detects extensive white matter damage. To improve prognostic capabilities, we evaluate the T1-weighted/T2-weighted (T1w/T2w) ratio, a measure of white matter integrity computable from clinical MRI sequences, in NMDAR encephalitis and examine its associations with
-
Understanding the pathophysiology of idiopathic intracranial hypertension (IIH): a review of recent developments J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Blake D Colman, Frederique Boonstra, Minh NL Nguyen, Subahari Raviskanthan, Priya Sumithran, Owen White, Elspeth J Hutton, Joanne Fielding, Anneke van der Walt
Idiopathic intracranial hypertension (IIH) is a condition of significant morbidity and rising prevalence. It typically affects young people living with obesity, mostly women of reproductive age, and can present with headaches, visual abnormalities, tinnitus and cognitive dysfunction. Raised intracranial pressure without a secondary identified cause remains a key diagnostic feature of this condition
-
Dementia prevention: the Mendelian randomisation perspective J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 Emma Louise Anderson, Neil M Davies, Roxanna Korologou-Linden, Mika Kivimäki
Understanding the causes of Alzheimer’s disease and related dementias remains a challenge. Observational studies investigating dementia risk factors are limited by the pervasive issues of confounding, reverse causation and selection biases. Conducting randomised controlled trials for dementia prevention is often impractical due to the long prodromal phase and the inability to randomise many potential
-
Correction: ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-04-01 BMJ Publishing Group Ltd
Antonini A, Barone P, Bonuccelli U, et al . ICARUS study: …
-
Revisiting the jumping to conclusions bias in functional movement disorders J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-07 Raquel Sainz-Amo, Jessenia Morillo-González, Jorge Gómez-Corral, Cristina Moreno, Araceli Alonso Cánovas, Juan Carlos Martinez Castrillo, Mark J Edwards, Daniel Hernández-Huerta, Isabel Pareés
Functional movement disorders (FMD) are part of the spectrum of functional neurological disorders (FND), which are common and disabling. Nowadays, it is widely accepted that key aspects of the underlying pathophysiology include the tendency to form abnormal beliefs about symptoms, disturbance of attentional control and disruption of mechanisms regulating sense of agency.1 ‘Jumping to conclusions’ bias
-
Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI J. Neurol. Neurosurg. Psychiatry (IF 11.0) Pub Date : 2024-03-07 Jing Jing, Zhe Zhang, Lei Su, Chenyang Gao, Ai Guo, Xinyao Liu, Huabing Wang, Xinghu Zhang, Yaou Liu, Giancarlo Comi, Emmanuelle Waubant, Fu-Dong Shi, De-Cai Tian
Background Although trigeminal nerve involvement is a characteristic of multiple sclerosis (MS), its prevalence across studies varies greatly due to MRI resolution and cohort selection bias. The mechanism behind the site specificity of trigeminal nerve injury is still unclear. We aim to determine the prevalence of trigeminal nerve involvement in patients with MS in a consecutive 7T brain MRI cohort